pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 It has also invested another $100 million in the three-year-old Cambridge, Massachusetts-based biotech, by participating in a $221 million Series B round.

Vaccines 98

Vaccines Packaging 98

pharmaphorum

DECEMBER 16, 2022

New category. The PM Society is delighted to announce a brand new, free of charge, category in the PM Society Awards 2023. This category has come about from a collaboration between the PM Society, the IPA, and ISBA, in connection with the Pitch Positive Pledge campaign. PM Society Awards.

Communication 52

Communication 52

pharmaphorum

JUNE 20, 2022

The paper says its source is the usual “people familiar with the matter” and stresses that a deal isn’t imminent, noting the regulatory challenges that may be faced given the strong position of both companies in the oncology category. It shows this is in fact a real issue holding some corners of biotech back.

105

105

pharmaphorum

JUNE 16, 2022

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to China’s HIBio. It also gets a $15 million signing fee related to MOR210.

104

104

pharmaphorum

FEBRUARY 3, 2021

New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last year, with investment levels soaring to £2.8 The successful year means many UK biotechs are well capitalised as we head into 2021 with continuing high levels of global economic uncertainty,” says the report. billion ($3.8

Vaccines 110

Vaccines Drug Development 110

pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . It’s also pledging milestones of up to $245 million per target, giving the entire deal an overall value of up to $1.25

Diabetes 75

Diabetes 75

pharmaphorum

AUGUST 5, 2022

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

Immunity 104

Immunity Immunization Drug Development 104

pharmaphorum

MAY 20, 2021

BMS wants to harness Exscientia’s tech to discover small-molecule drugs across a range of therapeutic categories – including immunology and oncology – and is promising another $125 million in near- and mid-term milestones to the project if all goes well. All told, the value of the deal could be as much as $1.2

68

68

pharmaphorum

SEPTEMBER 28, 2022

Roche’s Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech’s programmable T cell-based therapies platform. Roche may be a relative latecomer to the cell therapy category, but it’s sparing no expense to build a position within it.

58

58

pharmaphorum

DECEMBER 2, 2021

The project is further evidence of a re-entry by GSK into neuroscience, a category that it has largely retreated from over the last decade in favour of investing more in cancer, vaccines and infectious disease, immunology and respiratory medicines. Milestone payments tied to progress of the two drugs could add another $1.5 billion to the pot.

Vaccines 93

Vaccines 93

pharmaphorum

JANUARY 27, 2023

The UK BioIndustry Association (BIA) and data and insights company Clarivate have released their annual UK Biotech Financing report – and, on the whole, the findings are not positive. While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

SEPTEMBER 12, 2022

At the ESMO congress the German biotech reported updated results from a phase 1/2 trial of its lead candidate BNT-211 for solid tumours, which consists of a CAR-T directed at the antigen Claudin-6 on cancer cells, coupled with an mRNA vaccine (CARVac) designed to amplify the activity of the CAR-T.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

APRIL 13, 2022

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech’s shares skywards. GSK is paying $55 per share in cash for Sierra – a 39% premium to its closing share price yesterday – which values the company at around $1.9

Vaccines 105

Vaccines 105

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4

97

97

pharmaphorum

NOVEMBER 22, 2022

The Series D comes a little over 18 months after the six-year-old biotech’s third-round financing netted it around $107 million, taking its total raised to date north of $360 million. Ut comes just as FogPharma is preparing to start clinical trials of alpha-helical polypeptide candidate FOG-001. According to FogPharma, in the U.

Packaging 52

Packaging Compounding Drug Development 52

pharmaphorum

DECEMBER 8, 2021

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JANUARY 13, 2022

The UK-headquartered pharma is buying into a drug discovery platform developed by Boston, US biotech Scorpion Therapeutics, paying $75 million upfront to get the ball rolling on the partnership, with undisclosed option fees and milestone payments also on offer.

58

58

pharmaphorum

AUGUST 3, 2022

The Adaptimmune partnership followed a $2 billion alliance – including $300 million paid upfront – with Adaptive Biotech focusing on TCR therapies for solid tumours. Roche may be a latecomer to the cell therapy category – but it’s sparing no expense to build a position within it. Antibody for prurigo nodularis.

98

98

pharmaphorum

JUNE 1, 2022

O-glycoproteins with truncated O-glycans are absent from normal tissues but are present in 60-80% of human epithelial cancers, according to the biotech. That’s a very broad category, spanning lung, breast, ovarian, gastric, colon, and pancreatic solid tumours.

98

98

pharmaphorum

JULY 16, 2021

French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for $28 million upfront. . The drug has since been discontinued.

89

89

pharmaphorum

AUGUST 1, 2022

Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Marengo Therapeutics. The French pharma group has also promised around $1.6

52

52

pharmaphorum

MAY 5, 2022

One key example is the recently-introduced Access to Prescription Digital Therapeutics Act of 2022, which aims to officially define prescription digital therapeutics (PDTx) at the federal level and establish new Medicare and Medicaid benefit categories for the category. Similar initiatives are underway in German and France, he said.

Health Insurance Companies 52

Health Insurance Companies 52

pharmaphorum

MAY 9, 2022

“At this time, the facts are still uncertain, and our decisions will be guided by the outcome of our investigation,” said Nancy Simonian, chair of the biotech’s nominating and corporate governance committee. billion last year.

52

52

pharmaphorum

SEPTEMBER 30, 2022

Novo Nordisk follows a number of other companies into the category, notably Roche which has acquired two NLRP3 inhibitor companies, licensing both peripherally-restricted and centrally-acting candidates. Novartis, meanwhile, bought US biotech IFM Tre – a subsidiary of IFM Therapeutics – in a deal worth up to $1.58

Drug Development 58

Drug Development 58

pharmaphorum

NOVEMBER 22, 2022

Since then, the BCMA category has become more crowded, with two approved CAR-T therapies – Bristol-Myers Squibb/bluebird bio’s Abecma (idecabtagene vicleucel) and Johnson & Johnson/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel) – as well as J&J’s BCMAxCD3 bispecific antibody Tecvayli (teclistamab).

105

105

pharmaphorum

SEPTEMBER 2, 2022

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 The biotech went public via a $278 million IPO in 2020. Novo Nordisk licensed rights to EPI01 from EpiDestiny in 2018, paying $400 million for rights to the drug in haemaglobinopathies, while the biotech retained rights in oncology.

Diabetes 52

Diabetes 52

Drug Channels

JUNE 26, 2023

Cannot be combined with special category rates or other offers. This is a critical opportunity to navigate these complex yet beneficial partnerships with both health systems and life science companies together. Other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc.,

Biosimilars 63

Biosimilars 63

pharmaphorum

MAY 9, 2022

The new company – dubbed eureKING – plans to raise €150 million ($158 million) that will be used to buy up companies that operate in the European contract development and manufacturing organisation (CDMO) category. eureKARE initiated and is supporting the project.

58

58

pharmaphorum

APRIL 12, 2022

JDQ443 achieved a 57% overall response rate at a dose of 200mg given twice daily in the KontRASt-01 study, with a “favourable” side effect profile, and while Novartis is playing catch-up in the KRAS G12C inhibitor category the company thinks its drug could be best in class.

98

98

Express Pharma

MAY 15, 2023

VC investments decreased by 45.8 per cent in April 2023, compared to April 2022 The healthcare industry reported 93 venture capital (VC) deals worth $1.7 billion in April 2023, compared to the last 12-month average (April 2022 to March 2023) of 148 deals worth $2.7

93

93

pharmaphorum

AUGUST 20, 2021

The cash injection and BMS alliance have made Exscientia one of the most well-funded biotechs in the AI category and allowed it to bulk up its capabilities with the acquisition of Austrian rival Allcyte for $61 million in June.

Immunity 98

Immunity Immunization 98

pharmaphorum

OCTOBER 18, 2022

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).

Diabetes 52

Diabetes 52

pharmaphorum

MAY 9, 2022

J&J’s Janssen pharmaceuticals division said it will continue to work with the Danish biotech on vaccines targeting HIV and Ebola , but is prioritising its work in HBV on “alternative investigational vaccine platforms and therapeutics.” ” The partners’ HPV candidate had advanced into phase 1/2 clinical trials.

Vaccines 52

Vaccines 52

pharmaphorum

JUNE 2, 2021

Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 What is effectively the sale of a big chunk MorphoSys future revenues in return for a pair of externally developed experimental therapies seems to have spooked shareholders, and the biotech’s stock price was down nearly 15% after the news broke.

58

58

Drug Channels

SEPTEMBER 18, 2023

Offer applies to current rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Tom Hiney, Privacy Counsel , Blueprint Medicines Matt Howatt, Assistant U.S. Attorney , U.S. Comprehensive Content and Dynamic Features Include : 2.5 Register today.

67

67

pharmaphorum

MAY 13, 2022

The Belgian biotech said today it had received a complete response letter from the US regulator saying it “cannot approve the application in its current form” because observations in FDA inspections have to be resolved beforehand.

52

52

pharmaphorum

NOVEMBER 4, 2022

Neuroscience is one of Boehringer’s core therapeutic categories, with commercial products like Sifrol/Mirapex (pramipexole) for Parkinson’s disease and a pipeline headed by Gly-T1 inhibitor iclepertin (BI 425809) for cognitive impairment associated with schizophrenia, in phase 3 testing.

Drug Development 58

Drug Development 58